Will Microplasmin Injections Transform Treatment of Vitreomacular Adhesion (Traction) and Macular Hole?
October 9, 2010
Last month, ThromboGenics NV presented the results from the successful microplasmin MIVI-TRUST Phase III program at the EURETINA (European Society of Retina Specialists) Congress in Paris, France (MIVI-TRUST is short for “Microplasmin for IntraVitreous Injection-Traction Release without Surgical Treatment”).
The MIVI-TRUST program is the largest interventional clinical program ever performed to specifically evaluate the vitreoretinal interface in patients with retinal disorders, involving a total of 652 patients at 90 centers across the U.S. and Europe.
The results showed the potential of microplasmin injections to transform the treatment of a range of retinal disorders. Specifically, the Phase III program showed that microplasmin injections:
- Were successful in resolving vitreomacular adhesion (VMA) (also known as vitreomacular traction)
- Were able to cure full thickness macular hole (FTMH) without the need for surgery
- Delivered an improvement in the vision of patients without the need for surgery
- Were safe and well tolerated; there was no evidence of an increased risk of retinal tear or detachment
Read the full ThromboGenics release here (PDF).
You might also enjoy...
- ThromboGenics Completes Patient Enrollment in Microplasmin Trial
- ThromboGenics Announces Testing of Medical Treatment for Vitreomacular Adhesions Underway
- Ocriplasmin Approved by FDA to Treat Vitreomacular Adhesion
- ThromboGenics Announces New Phase III Ocriplasmin Data Presented at the 2011 Annual Meeting of the American Society of Retina Specialists (ASRS)
- Regeneron Commence Study of VEGF Trap-Eye for CVRO Treatment
Jump down to form below to submit your own comments